Konstanze Diefenbach, Head of R&D for Bayer Radiology, and Franziska Lobig, commercial lead for AI innovation at Bayer, outline the company’s latest advancements at ECR 2025. They highlight the promising phase three trial data for the MRI contrast agent Gadoquatrane, which achieves comparable diagnostic efficacy for central nervous system pathologies using only 60% of the gadolinium dose. This reduction is particularly beneficial for patients undergoing multiple MRIs, including those with central nervous system disorders and pediatric cases.
In addition, they delve into Bayer’s comprehensive AI innovation platform, designed to streamline the development of advanced imaging solutions. Through strategic collaborations, including a strong partnership with Google Cloud and valuable insights gathered from hackathons, the platform is continuously refined to address regulatory, clinical, and technical challenges, ultimately enhancing efficiency in radiology and paving the way for more personalized patient care.
